Mapmygenome has run certified genomics and diagnostic labs out of Hyderabad for more than a decade, sold a saliva-based DNA test since 2013, and counts Ratan Tata among its early individual backers. Its revenue for the year ended March 2025 was still just ₹31.2 crore (about $3.25 million at $1 ≈ ₹96.0, 18 September 2026, Trading Economics) — up a mere 1.94% on the year before, according to Inc42’s review of the company’s filings.
That is the contradiction sitting at the centre of this company. A founder who had already built and sold one genomics business before starting this one, a product category she is credited with creating in India, backers who include a Google India managing director and one of the country’s most recognisable industrialists — and, twelve years on, a business that is still small enough that a single mid-sized hospital’s annual revenue could dwarf it. In May 2025, Mapmygenome acquired a Canadian microbiome research lab and said it was doing so on the way to an Indian stock market listing “later this year.” As of this writing, that listing has not happened. This is the story of a company that keeps finding new things to sell — pharmacogenomics, prenatal screening, pandemic-era RT-PCR tests, contract microbiome research — without any one of them yet turning it into a large business.
Quick facts
| Company | Mapmygenome India Limited |
| Founded | Incorporated 10 February 2012; Genomepatri and the consumer brand launched in 2013 |
| Founder(s) | Anu Acharya (Founder-CEO); Subash Lingareddy (co-founder) |
| Businesses | Preventive and consumer genomics testing, pharmacogenomics, diagnostic and prenatal testing, microbiome contract research (from 2025) |
| Latest FY revenue | ₹31.2 crore (about $3.25 million), FY25 (year ended March 2025) |
| Latest FY profit/loss | Not reliably disclosed in the sources reviewed for this piece |
| Listed | Private. A listing on the Indian market was targeted for “later this year” as of a May 2025 company statement; not completed as of September 2026 |
| Market value / last valuation | Not publicly disclosed. Lifetime funding is reported at $1.69 million across 4 rounds (Tracxn) or $2.3 million across 2 rounds (Inc42) — trackers disagree |
| Key shareholders or CEO | Anu Acharya, Founder-CEO; early individual backers reported to include Ratan Tata and Rajan Anandan |
What they do
Mapmygenome runs NABL- and CAP-accredited laboratories in Hyderabad that turn a saliva or blood sample into a genetic report. Its oldest and best-known product, Genomepatri, screens for genetic predisposition to more than a hundred diseases, traits, drug responses and carrier conditions, and is sold directly to consumers online as well as through hospitals, wellness clinics and corporate health programmes. Around that core, the company has built out a wider testing menu: MedicaMap, a pharmacogenomics report that checks how a person’s genes affect their response to more than 165 US-FDA-approved drugs; OncoMap, a panel covering more than 15 cancer types common in India; non-invasive prenatal testing (NIPT) for expectant mothers; and lifestyle-oriented tests such as CardioMap, BeautyMap and MyFitGene. Its buyer is, broadly, an urban Indian who can afford a discretionary health test and a doctor or hospital that wants a genetic panel to offer patients rather than build in-house. Since May 2025, through the acquisition of Canada’s Microbiome Insights, it also sells microbiome sequencing and research services to biotech and pharmaceutical clients outside India.
The origin
Anu Acharya was not new to genomics when she started Mapmygenome. An IIT Kharagpur engineering graduate who went on to earn a master’s degree in physics and management information systems from the University of Illinois at Chicago, she had already founded and run Ocimum Bio Solutions from November 2000, a Hyderabad-based genomics-outsourcing company that built bioinformatics software and, later, laboratory devices for discovery and diagnostics clients. She led Ocimum as CEO for thirteen years. The insight behind Mapmygenome, launched in 2013 once Acharya stepped back from Ocimum, was that the genomics expertise India had built up serving Western pharmaceutical and research clients as an outsourcing destination could instead be pointed inward, at Indian consumers and Indian hospitals, who had almost no access to predictive genetic testing of their own. Genomepatri, run on Illumina genotyping arrays and paired with genetic counselling, was built to be that first product: a single saliva sample turned into a lifetime risk map, sold with the founder’s stated ambition, repeated in her own company’s materials, of wanting to “touch 100 million lives.” It was a founding insight built on a market that, unlike outsourced bioinformatics, did not yet exist in India and had to be created from nothing.
The struggle years
Building a market from nothing took longer, and cost more relative to the company’s size, than the founding pitch suggested. By 2018, five years after launch, Mapmygenome had processed genetic samples for more than 10,000 people and was projecting roughly ₹6 crore in revenue for the year, with EBITDA still negative, according to a Forbes India profile of Acharya published that year. That profile also recorded Acharya’s own description of the difficulty: operating “in an area that is difficult for people to understand,” compounded, in her account, by the extra scepticism she faced raising money and building credibility as a woman founder in Indian biotech. The company tried to solve the adoption problem more than once. In December 2015, it introduced Genomepatri Lite, a scaled-down, cheaper version of the flagship test aimed at reaching a wider customer base — an acknowledgement that the original test’s price point was keeping the addressable market small. That did not fully solve it either: by February 2022, Mapmygenome cut the price of Genomepatri itself by 56%, from ₹15,000 to ₹7,999, with Acharya framing the move around “MapmyGenome’s mission to democratise genomics in India” and crediting an in-house genotyping chip, developed over eight years, for making the cut possible. A company does not slash its flagship product’s price by more than half, nine years after launch, if that product had already found a large and willing market at the old price.
The turning point
The event that forced Mapmygenome to become a different kind of company was the COVID-19 pandemic. In April 2020, with its consumer wellness-testing business effectively frozen by lockdowns, the company became one of the private laboratories approved by the Indian Council of Medical Research to run COVID-19 diagnostic testing, repurposing lab infrastructure it had originally built for TB testing kit development, and launched a “Genomepatri Immunity Report” assessing genetic risk factors tied to COVID-19 severity. It ran testing operations at sites including Hyderabad’s international airport. The numbers on each side of that pivot show both what it gained and what it cost: a grant of about ₹53 lakh from the Action Covid-19 Team funded pooled-sample RT-PCR testing technology that cut per-test costs by an estimated 60% to 80%, and the company had to expand its team by roughly 30% to handle demand, absorbing higher spending on protective equipment, reagents and R&D along the way. On the other side of the ledger, the Indian government capped private COVID-19 test pricing at between ₹2,400 and ₹3,000, a level Acharya publicly argued did not account for the fixed overhead of running a compliant testing lab. The pandemic gave Mapmygenome a second, urgent line of business overnight; it also showed how thin the margin on that business could be once a price ceiling was set by regulators rather than the market.
The money behind it
Mapmygenome’s capital history is unusually light for a twelve-year-old life-sciences company, and much of what did come in arrived early.
- Founder capital: Anu Acharya is reported to have put in roughly $2 million of her own money by 2016 to keep the company running in its early years (Forbes India, 2018).
- Pre-Series A, March 2015: $1.1 million, the largest single disclosed round, from a group of named angel investors — Rajan Anandan (then managing director, Google India), Arihant Patni (managing director, Hive Technologies), Aarti Grover (managing director, CMS Computers) and Satveer Singh Thakral (CEO, Singapore Angel Network) — with Avendus Wealth Management advising the deal. Acharya said at the time the money would fund India and international scale-up, hiring and research assets (Mapmygenome company blog, republishing the original YourStory report, March 2015).
- Follow-on angel backing, 2015–2016: smaller rounds that added Ratan Tata to the investor list alongside Rajan Anandan, taking the company to a reported 34 investors in total, 30 of them individual angels and 4 institutional (Tracxn).
- Total lifetime funding: reported as $1.69 million across four rounds by Tracxn, and as $2.3 million across two rounds, with the most recent dated June 2015, by Inc42. The two trackers do not reconcile, and Mapmygenome has not published a single consolidated funding figure in the sources reviewed for this piece.
- No fresh primary institutional funding round has been publicly reported since 2015–16 — a decade in which the company’s next major capital event has been an acquisition it made, rather than money it raised.
- May 2025: Mapmygenome acquired Canada’s Microbiome Insights, a CAP-accredited microbiome contract-research lab that has worked with more than 600 clients on over 1,000 studies. Deal terms were not disclosed. Acharya described it as building toward “our listing on the Indian market later this year” (company press release, 29 May 2025).
How it makes money
Mapmygenome earns money by running its own wet labs and selling the tests those labs produce, rather than by licensing software or data — closer to a diagnostics company than to a pure genomics app. That means it carries real lab capital and operating costs (sequencing and genotyping equipment, reagents, NABL/CAP accreditation and compliance, trained lab and counselling staff) that a software-only personal-genomics business would not.
- Direct-to-consumer testing: Genomepatri and its lifestyle variants (BeautyMap, MyFitGene, CardioMap, Genomepatri Heritage) sold through the company’s own website, priced from ₹7,999 for the core test since the February 2022 price cut.
- Hospital and corporate channel sales: the same test menu distributed through hospitals, wellness clinics and corporate health programmes rather than sold one customer at a time, spreading acquisition cost across an institutional partner.
- Pharmacogenomics: MedicaMap, priced and positioned as a clinical decision-support tool for doctors prescribing across psychiatry, oncology, cardiology, diabetology and other specialties, covering response data for more than 165 US-FDA-approved drugs.
- Clinical and prenatal diagnostics: OncoMap (cancer-panel testing) and NIPT/prenatal screening, sold into a more conventional diagnostic-testing market alongside pathology chains rather than the wellness-testing category Genomepatri competes in.
- Pandemic-era diagnostics: ICMR-approved COVID-19 RT-PCR testing, a temporary but at-the-time significant revenue line built on existing lab infrastructure (2020 onward).
- Global contract research: microbiome sequencing and research services sold to biotech and pharmaceutical clients through the 2025 Microbiome Insights acquisition, the company’s first meaningful push to earn revenue outside India.
What outsiders tend to get wrong is treating Mapmygenome as a simple mail-a-tube-and-get-an-app-report consumer business, on the model of a global direct-to-consumer genomics brand. In practice, more of its test menu than the marketing suggests is sold B2B2C, through doctors, hospitals and corporates who become the actual purchasing decision-maker, and an increasing share of its ambition — the Microbiome Insights deal, the specialty diagnostic panels — sits closer to contract research and clinical diagnostics than to consumer wellness. Neither the company nor the trackers covering it publish a segment-wise revenue split or a disclosed take rate, so the exact weighting between these lines cannot be stated with a number here.
The numbers
| Metric | FY18 (as reported in 2018) | FY24 | FY25 |
| Revenue | ~6 (company-projected, per Forbes India) | 30.6 | 31.2 |
| Revenue growth, YoY | Company cited an 84% CAGR over the prior 3 years | — | +1.94% (Inc42); Tofler’s MCA-based tracker rounds this to +2% |
| Net profit/(loss) | EBITDA reported negative | Not reliably disclosed | Not reliably disclosed |
The gap in this table is deliberate. Multiple financial-data aggregators publish purported multi-year profit-and-loss tables for Mapmygenome, but cross-checking two of the best-known ones against each other during research for this piece produced internally inconsistent and mutually contradictory figures for the same fiscal years — a sign that the underlying line items are not reliably extracted from source filings. Rather than print numbers that could not be verified, this piece reports only the two most recent years for which independent sources (Inc42’s company profile and Tofler’s MCA-sourced summary) agree, plus a single, clearly caveated 2018 data point from a contemporaneous magazine profile. What is verifiable across that span is direction, not magnitude: a company that was still pre-profit and running on roughly ₹6 crore of revenue in 2018 had, by FY25, grown to just over ₹31 crore — real growth over seven years, but growth that had nearly flattened out by the most recent year measured, at under 2% year-on-year.
Where the money comes from
Mapmygenome does not publish a geography or channel-wise revenue split, so this section describes the shape of its business rather than a numerical breakdown that cannot be sourced.
- Geography: overwhelmingly India-focused for most of its history, run out of a single Hyderabad hub, with the Microbiome Insights acquisition in May 2025 giving it its first owned laboratory and client base outside the country, in Canada, aimed at North American biotech and pharmaceutical customers.
- Customer type: a mix the company’s own marketing does not emphasise — individual consumers buying wellness and ancestry-style tests directly, alongside doctors, hospitals and corporate wellness programmes that act as the actual purchasing channel for a meaningful share of its test menu, plus, at times, government and public-health bodies during the pandemic testing period.
- The surprise: a company best known publicly for a consumer DNA test has, at different points in its history, earned a significant share of revenue from lines that have nothing to do with that consumer product — outsourced-style pandemic diagnostics in 2020–21, and now international contract microbiome research from 2025 — rather than from Genomepatri scaling on its own.
The risks
- Regulatory exposure on genetic data. India’s Digital Personal Data Protection Act, 2023, together with the Digital Personal Data Protection Rules notified in 2025, treats highly sensitive categories such as genetic data with elevated compliance expectations, and legal commentary published in early 2026 has specifically flagged genetic information as warranting internal high-risk classification, data-protection impact assessments and detailed processing records (SCC Online, January 2026; Live Law analysis, 2026). A company that stores raw genomic data for its customer base carries a compliance and breach-reputation exposure that a typical consumer-app business does not.
- Growth that has nearly stalled at a small base. Revenue rose just 1.94% between FY24 and FY25, to ₹31.2 crore (Inc42, corroborated by Tofler’s MCA-based tracker). A twelve-year-old company growing at under 2% a year, on a base this size, has little organic momentum to point to ahead of a planned public listing, and would need either a new product line or the newly acquired Canadian business to move that number meaningfully.
- A stated IPO timeline that has already slipped. In its own May 2025 press release, Mapmygenome said the Microbiome Insights acquisition was building toward “our listing on the Indian market later this year” — meaning 2025. No draft prospectus filing or listing date for the company could be found in public IPO trackers as of September 2026, a year after that statement. The company has not raised a fresh primary funding round since around 2015–16, so a delayed listing removes what looks like its main near-term route to new growth capital.
The takeaway
Mapmygenome’s history is a reminder that being early to a category is not the same as the category being ready for you. Anu Acharya built a genuinely novel product for the Indian market in 2013 and kept the company alive for more than a decade in a segment — predictive consumer genomics — that Indian buyers, by the company’s own repeated actions, were not yet buying at the price or in the volume the original plan assumed. What kept Mapmygenome going was not one big breakout year but a willingness to keep changing what it actually sold: a cheaper version of the flagship test, a pharmacogenomics panel, a pandemic testing lab, and now international contract research bought rather than built. The transferable lesson is not that pivoting is a strength in itself; it is that when a market takes far longer to mature than a founder’s original timeline assumed, survival can depend on finding adjacent, sellable uses for the same underlying lab and expertise, again and again, rather than waiting for the first product to eventually take off.
Frequently asked questions
Who founded Mapmygenome and when?
Anu Acharya founded Mapmygenome, which was incorporated on 10 February 2012 and launched its flagship Genomepatri test in 2013. She had earlier founded and run Ocimum Bio Solutions, a genomics-outsourcing company, from 2000 to 2013.
What does Mapmygenome actually sell?
Genetic testing products and services: consumer wellness and predisposition tests (Genomepatri and variants), a pharmacogenomics panel (MedicaMap), cancer and prenatal diagnostic tests, and, since May 2025, microbiome contract research through its acquisition of Canada’s Microbiome Insights. It also ran COVID-19 RT-PCR testing during the pandemic.
How much money has Mapmygenome raised, and is it profitable?
Reported lifetime funding ranges from $1.69 million (Tracxn) to $2.3 million (Inc42), with the largest disclosed round a $1.1 million pre-Series A in March 2015. Its profit or loss is not reliably disclosed in public sources; FY25 revenue was ₹31.2 crore, up 1.94% on FY24.
Is Mapmygenome going public?
The company said in May 2025 that it was working toward a listing on the Indian market “later this year.” As of September 2026, no draft prospectus or listing date had appeared in public IPO trackers reviewed for this piece.
Who are Mapmygenome’s investors?
Named early backers include Rajan Anandan (then managing director, Google India), Arihant Patni of Hive Technologies, Aarti Grover of CMS Computers, Satveer Singh Thakral of the Singapore Angel Network, and, in a later round, Ratan Tata, according to Tracxn’s investor list and the company’s own funding announcements.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Forbes India, “2018 W-Power Trailblazers: Anu Acharya hopes to save a million lives by decoding genetic makeup”, 2018
- Wikipedia, “Anuradha Acharya”, accessed September 2026
- Mapmygenome company blog (republishing YourStory), “Hyderabad-based Mapmygenome raises $1.1 million funding in pre-series A round”, March 2015
- Mapmygenome company blog, “Mapmygenome announced a drop of 56% in its flagship product Genomepatri”, February 2022
- GenomeWeb, “India’s Mapmygenome Rolls Out Genomepatri Lite to Expand Consumer Genomics Menu”, December 2015
- Inc42, “MapMyGenome — Funding, Revenue & Investors” company profile, accessed September 2026
- Tofler, “Mapmygenome India Limited” company financial summary, accessed September 2026
- Tracxn, “MapMyGenome — Funding Rounds & List of Investors”, accessed September 2026
- Inc42, “Mapmygenome Looks To Crack India’s Genetic Code In Covid-19 Fight”, 2020/2021
- PR Newswire, “Mapmygenome cements global leadership in Genomics with strategic acquisition of Canada’s Microbiome Insights”, 29 May 2025
- YourStory, “Mapmygenome acquires Canada’s Microbiome Insights ahead of IPO”, May 2025
- SCC Online, “Genetic Data Protection under DPDPA: Risks, Research & Compliance”, January 2026
- Live Law, “Genetic Data Processing Under DPDPA”, 2026
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.
